
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc has demonstrated a significant increase in demand for its NeXT Personal diagnostic test, with a 41% quarter-over-quarter rise in volumes in Q4'25, strongly supported by its partnership with Tempus, which is expected to enhance marketing efforts. Additionally, the recent announcement of Medicare coverage for the NeXT Personal MRD test in breast cancer represents a pivotal milestone, further enhancing the test's market accessibility and potential for revenue growth. The company's ability to detect minimal residual disease (MRD) with high sensitivity in the 1-100ppm range, along with a strategic approach to managing cash burn during the reimbursement process, suggests a solid foundation for sustainable growth and an undervaluation relative to market potential.
Bears say
Personalis Inc. is facing a challenging financial landscape, as evidenced by its lowered revenue guidance for 2025, now projected at $68 million to $73 million, reflecting a year-over-year decline of 12% to 5%. Additionally, the company has encountered logistical issues with global samples and a broader slowdown in the biopharma sector, which could adversely impact demand for its sequencing and data analysis services. Furthermore, despite raising $109 million in net proceeds from its ATM facility in Q4'25, the overall financial stability remains under threat due to significant losses and ongoing concerns regarding profitability and revenue generation.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares